Marla Weetall
Marla Weetall has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Art Branstrom
PTC Therapeutics, Inc
49 shared publications - Azhar Ali
Cancer Science Institute of Singapore, National University of Singapore, Singapore
49 shared publications - Barbara Storti
NEST, Scuola Normale Superiore and Istituto Nanoscienze-CNR, Piazza San Silvestro 12, 56127 Pisa, Italy
49 shared publications - Daniel Geoffrey Tenen
Harvard Stem Cell Institute, Harvard Medical School, Boston, USA
49 shared publications - Daniela Sanchez Bassères
Biochemistry Department Chemistry Institute, São Paulo University São Paulo Brazil
49 shared publications - Elena Levantini
Institute of Biomedical Technologies, National Research Council (CNR) Pisa Italy
49 shared publications
Latest Publications
- 19 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (863)
MAPT splicing modulators reduce 4R tau and rescue tauopathy phenotypes in human neurons and in a mouse model
Tauopathies are neurodegenerative diseases characterized by the pathological accumulation of microtubule-associated protein tau (MAPT) in the brain. These disorders, like frontotemporal dementia (FTD-tau), currently lack effective therapies and can occur sporadically or be inherited when associated with MAPT gene mutations. Exon 10 and adjacent introns of the MAPT gene are a hotspot for pathogenic variants, including splicing mutations that enhance exon 10 inclusion and increase 4R tau expression and 4R-specific gain-of-function mutations that generate aggregation-prone tau. For these 4R tauopathies, a targeted messenger RNA (mRNA) splicing approach that promotes exon 10 exclusion may offer therapeutic benefit. We have developed splicing modulator compounds (SMCs) that promote MAPT exon 10 exclusion and demonstrated their efficacy in neurons derived from patients with FTD carrying the tau Pro 301 →Leu (P301L) gain-of-function mutation or the tau Ser 305 →Asn (S305N) splicing mutation. Treatment with SMC reduced 4R tau expression and decreased the accumulation of hyperphosphorylated tau (pTau) and oligomeric and insoluble tau proteoforms, thereby rescuing tau-associated neuronal toxicity. A lead SMC corrected the 3R/4R splice ratio in vivo and reduced pTau in the brain of a human gene-replacement mouse model expressing the tau Asn 279 →Lys (N279K) splicing mutation. These findings support the therapeutic potential of this class of small molecules and establish MAPT pre-mRNA splicing modulation as a promising strategy for the treatment of 4R tauopathies.
- 19 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (863)
MAPT splicing modulators reduce 4R tau and rescue tauopathy phenotypes in human neurons and in a mouse model
Tauopathies are neurodegenerative diseases characterized by the pathological accumulation of microtubule-associated protein tau (MAPT) in the brain. These disorders, like frontotemporal dementia (FTD-tau), currently lack effective therapies and can occur sporadically or be inherited when associated with MAPT gene mutations. Exon 10 and adjacent introns of the MAPT gene are a hotspot for pathogenic variants, including splicing mutations that enhance exon 10 inclusion and increase 4R tau expression and 4R-specific gain-of-function mutations that generate aggregation-prone tau. For these 4R tauopathies, a targeted messenger RNA (mRNA) splicing approach that promotes exon 10 exclusion may offer therapeutic benefit. We have developed splicing modulator compounds (SMCs) that promote MAPT exon 10 exclusion and demonstrated their efficacy in neurons derived from patients with FTD carrying the tau Pro 301 →Leu (P301L) gain-of-function mutation or the tau Ser 305 →Asn (S305N) splicing mutation. Treatment with SMC reduced 4R tau expression and decreased the accumulation of hyperphosphorylated tau (pTau) and oligomeric and insoluble tau proteoforms, thereby rescuing tau-associated neuronal toxicity. A lead SMC corrected the 3R/4R splice ratio in vivo and reduced pTau in the brain of a human gene-replacement mouse model expressing the tau Asn 279 →Lys (N279K) splicing mutation. These findings support the therapeutic potential of this class of small molecules and establish MAPT pre-mRNA splicing modulation as a promising strategy for the treatment of 4R tauopathies.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 2: Experimental optimization prior to clonal tacking of SU_MB002 with DNA barcoding library.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 2: Experimental optimization prior to clonal tacking of SU_MB002 with DNA barcoding library.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Purpose:Medulloblastoma is a common pediatric brain tumor with distinct molecular subgroups. Among them, group 3 medulloblastoma is associated with increased recurrence, metastatic potential, and poor patient outcomes. Small-molecule inhibitors targeting B cell–specific Moloney murine leukemia virus insertion site 1 (BMI1) have demonstrated efficacy against several types of malignant tumors, including pediatric medulloblastoma. Although our previously published in vivo study provided a promising proof of concept for the therapeutic targeting of BMI1 in group 3 medulloblastoma with small-molecule inhibitors, it is not sufficient to eradicate the tumor.Experimental Design:In this study, following preclinical validation of BMI1 inhibitor PTC596, DNA barcoding technology was leveraged to profile in vivo clonal dynamics of group 3 medulloblastoma in response to the established chemoradiotherapy regimen alone and in combination with PTC596. Following demonstration of a small number of treatment-refractory clones, we sought to identify potential druggable molecular vulnerabilities by utilizing phosphoproteomic profiling and genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening.Results:By comparing the changes in the phosphorylation pattern of key signaling kinases after PTC596 treatment with the list of sensitizer genes from in vitro genome-wide CRISPR/CRISPR-associated protein 9 screen and with the essential genes in human neural stem cells, we identified several context-specific regulators of mTOR, AKT, and PLK1 pathways. Subsequently, targeting the PI3K pathway with enzastaurin was most amenable to synergistic targeting alongside BMI1 inhibition.Conclusions:This work provides the foundation for clinical validation of small-molecule inhibitors synergistic with PTC596 to improve the durability of remissions and extend the survival of patients with treatment-refractory group 3 medulloblastoma.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Purpose:Medulloblastoma is a common pediatric brain tumor with distinct molecular subgroups. Among them, group 3 medulloblastoma is associated with increased recurrence, metastatic potential, and poor patient outcomes. Small-molecule inhibitors targeting B cell–specific Moloney murine leukemia virus insertion site 1 (BMI1) have demonstrated efficacy against several types of malignant tumors, including pediatric medulloblastoma. Although our previously published in vivo study provided a promising proof of concept for the therapeutic targeting of BMI1 in group 3 medulloblastoma with small-molecule inhibitors, it is not sufficient to eradicate the tumor.Experimental Design:In this study, following preclinical validation of BMI1 inhibitor PTC596, DNA barcoding technology was leveraged to profile in vivo clonal dynamics of group 3 medulloblastoma in response to the established chemoradiotherapy regimen alone and in combination with PTC596. Following demonstration of a small number of treatment-refractory clones, we sought to identify potential druggable molecular vulnerabilities by utilizing phosphoproteomic profiling and genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening.Results:By comparing the changes in the phosphorylation pattern of key signaling kinases after PTC596 treatment with the list of sensitizer genes from in vitro genome-wide CRISPR/CRISPR-associated protein 9 screen and with the essential genes in human neural stem cells, we identified several context-specific regulators of mTOR, AKT, and PLK1 pathways. Subsequently, targeting the PI3K pathway with enzastaurin was most amenable to synergistic targeting alongside BMI1 inhibition.Conclusions:This work provides the foundation for clinical validation of small-molecule inhibitors synergistic with PTC596 to improve the durability of remissions and extend the survival of patients with treatment-refractory group 3 medulloblastoma.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 6: Immunohistochemical profiling of changes in phospho-AKT1 levels in response to treatment.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 6: Immunohistochemical profiling of changes in phospho-AKT1 levels in response to treatment.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 4: Assays evaluating the suitability of SU_MB002 for the in vitro genome-wide CRISPR-Cas9 screen
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 4: Assays evaluating the suitability of SU_MB002 for the in vitro genome-wide CRISPR-Cas9 screen
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 3: DNA barcode abundance
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 3: DNA barcode abundance
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 1: In vitro treatment of SU_MB002 with PTC596
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 1: In vitro treatment of SU_MB002 with PTC596
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 5: Changes in phosphorylation of select signaling kinases and distribution of gDNA across samples collected during in vitro CRISPR screen.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 5: Changes in phosphorylation of select signaling kinases and distribution of gDNA across samples collected during in vitro CRISPR screen.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 7: Dose response curves of small molecule inhibitors
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 7: Dose response curves of small molecule inhibitors
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Table 1: IC50 concentration of select small molecules inhibitors
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Table 1: IC50 concentration of select small molecules inhibitors